Literature DB >> 23381981

Fungal meningoencephalitis caused by Alternaria: a clinical case.

Cícero J C Silveira1, Joana Amaral, Rodrigo P Gorayeb, José Cabral, Teresa Pacheco.   

Abstract

Cerebral phaeohyphomycosis is an infrequent infectious condition associated with a high mortality rate. The authors describe a very rare case that occurred in an immunocompetent 18-year-old man who developed severe meningoencephalitis and arachnoiditis caused by Alternaria alternata, which were diagnosed in the context of difficult-to-treat hydrocephalus. Etiological diagnosis was made based on fungal culture and histopathologic examination. Empirical treatment consisted of an early aggressive antifungal combination therapy consisting of intravenous liposomal amphotericin B (5 mg/kg per day) and voriconazole (4 mg/kg every 12 h), which initially induced a favorable response. Following the fungus identification, the choice for the combination of posaconazole (400 mg every 12 h) plus flucytosine (4000 mg/day) proved to be effective in the suppression of the signs and symptoms of this uncommon cerebral mycosis. At a 12-month follow-up visit no recurrence had occurred and posaconazole was then stopped.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23381981     DOI: 10.1007/s40261-012-0016-2

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  11 in total

Review 1.  Disseminated phaeohyphomycosis: review of an emerging mycosis.

Authors:  Sanjay G Revankar; Jan E Patterson; Deanna A Sutton; Renee Pullen; Michael G Rinaldi
Journal:  Clin Infect Dis       Date:  2002-01-09       Impact factor: 9.079

2.  Cerebral phaeohyphomycosis--a cure at what lengths?

Authors:  Dong Ming Li; G Sybren de Hoog
Journal:  Lancet Infect Dis       Date:  2009-06       Impact factor: 25.071

Review 3.  Successful therapy of cerebral phaeohyphomycosis due to Ramichloridium mackenziei with the new triazole posaconazole.

Authors:  H M Al-Abdely; A M Alkhunaizi; J A Al-Tawfiq; M Hassounah; M G Rinaldi; D A Sutton
Journal:  Med Mycol       Date:  2005-02       Impact factor: 4.076

4.  SCH 56592, amphotericin B, or itraconazole therapy of experimental murine cerebral phaeohyphomycosis due to Ramichloridium obovoideum ("Ramichloridium mackenziei").

Authors:  H M Al-Abdely; L Najvar; R Bocanegra; A Fothergill; D Loebenberg; M G Rinaldi; J R Graybill
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

Review 5.  Posaconazole: a broad-spectrum triazole antifungal.

Authors:  Harrys A Torres; Ray Y Hachem; Roy F Chemaly; Dimitrios P Kontoyiannis; Issam I Raad
Journal:  Lancet Infect Dis       Date:  2005-12       Impact factor: 25.071

Review 6.  Posaconazole.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2005       Impact factor: 9.546

7.  Alternaria infectoria brain abscess in a child with chronic granulomatous disease.

Authors:  E Hipolito; E Faria; A F Alves; G S de Hoog; J Anjos; T Gonçalves; P V Morais; H Estevão
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-09-25       Impact factor: 3.267

8.  Posaconazole therapy of disseminated phaeohyphomycosis in a murine model.

Authors:  John R Graybill; Laura K Najvar; Elizabeth Johnson; Rosie Bocanegra; David Loebenberg
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

9.  Brain abscess due to Cladophialophora bantiana.

Authors:  S R Jayakeerthi; M Dias; S Nagarathna; B Anandh; A Mahadevan; A Chandramuki
Journal:  Indian J Med Microbiol       Date:  2004 Jul-Sep       Impact factor: 0.985

Review 10.  Primary central nervous system phaeohyphomycosis: a review of 101 cases.

Authors:  Sanjay G Revankar; Deanna A Sutton; Michael G Rinaldi
Journal:  Clin Infect Dis       Date:  2003-12-19       Impact factor: 9.079

View more
  1 in total

1.  Cerebral phaeohyphomycosis caused by Alternaria spp.: A case report.

Authors:  Santiago Cardona; Soad Yusef; Edwin Silva; Gisell Bustos M; Isabel Torres M; Rafael Leal A; Andres Ceballos-Garzon; Diego Fernando Josa
Journal:  Med Mycol Case Rep       Date:  2019-12-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.